Milton Boyer Named President of OSO BioPharmaceuticals Manufacturing

Albuquerque, NM Feb 13, 2012 – Milton Boyer has been appointed president of OSO BioPharmaceuticals Manufacturing, LLC.
Boyer has been responsible for guiding business strategies and creating new growth opportunities at OsoBio since 2008, most recently as vice president of business development and sales. As part of his promotion, he joins OsoBio’s board of directors.
“Our mission at OsoBio remains focused on building an injectable drug contract manufacturing organization that distinguishes itself with world-class customer service,” said George Aitken-Davies, board member. “Milton has demonstrated continued commitment to this vision by developing strategic customer relationships and driving significantly increased visibility of OsoBio in the market. We are confident that Milton’s leadership skills will help us achieve the bold and ambitious goals we’ve set for 2012 and beyond.”
Boyer said his immediate priorities include continuing to update and expand OsoBio’s operational capabilities, toward which the company is making significant capital investments this year. He also intends to deepen OsoBio’s talent pool and drive operational efficiencies.
Boyer serves on the board of directors at the Drug, Chemical and Associated Technology Association (DCAT), the business development association whose membership is comprised of companies that manufacture, distribute or provide services to the pharmaceutical, chemical and related industries. He also is a member of the International Society of Pharmaceutical Engineers (ISPE) and the American Association of Pharmaceutical Scientists (AAPS).
With more than 20 years of professional experience within fine chemical and pharmaceutical business development, Boyer has developed special expertise in active pharmaceutical ingredients (APIs) and narcotic raw materials. He previously served as director of sales and marketing for Siegfried-USA and Chattem Chemicals Inc.